Product
Albumin-Bound Paclitaxel
8 clinical trials
10 indications
Indication
Advanced CancerIndication
Stomach CancerIndication
Gastroesophageal Junction CancerIndication
Pancreatic CancerIndication
Advanced Solid TumorIndication
Esophagogastric Junction AdenocarcinomaIndication
Lung CancerIndication
Triple-negative Breast CancerIndication
Oral Squamous Cell CarcinomaClinical trial
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination With Nivolumab or Standard of Care in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 1 Study of SRF617 in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-08-25
Clinical trial
A Phase Ib/II, Open-label Clinical Study to Evaluate the Safety, Tolerability and Antitumor Activities of IN10018+Standard Chemotherapy and IN10018+Standard Chemotherapy+KN046 in Subjects With Advanced Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multi-Center, Multi-Cohort Study of the Efficacy and Safety of Anlotinib, TQB2450, and Albumin-bound Paclitaxel in CLDN18.2-regimen-failed Gastric Cancer or Gastroesophageal Junction AdenocarcinomaStatus: Not yet recruiting, Estimated PCD: 2025-08-25
Clinical trial
A Single-Arm, Phase II Study of AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Prospective, Randomized, Open Label Clinical Study Evaluating Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-01-10
Clinical trial
Neoadjuvant Chemoimmunotherapy With Tislelizumab, Albumin-bound Paclitaxel, and Cisplatin in Locally Advanced Oral/Oropharyngeal Squamous Cell Carcinoma: A Prospective, Multicenter, Single-arm StudyStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS015 Combination Therapy in Patients With Advanced Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2025-11-30